ライフサイエンスコーパス: disease marker

1 nterhemispheric connectivity appears to be a disease marker.

2 ies to GAD might be the causative agent or a disease marker.

3 ct on clinical outcomes based on impact on a disease marker.

4 not been possible due to lack of a specific disease marker.

5 s disorder and could be useful as a biologic disease marker.

6 deposits, remain one of the least understood disease markers.

7 cals and for the clinical analysis of glycan disease markers.

8 se score (BDS) with subjective and objective disease markers.

9 sment of their clinical potential as cardiac disease markers.

10 IV-infected individuals, controlling for HIV disease markers.

11 seminated, >/=4 sulci), and key small vessel disease markers.

12 ich source of biological information such as disease markers.

13 te disease mechanisms and identify surrogate disease markers.

14 sensitive detection of infectious agents and disease markers.

15 of genotypes in candidate genes as potential disease markers.

16 and who exhibited lower levels of surrogate disease markers.

17 the sensitive and quantitative detection of disease markers.

18 ation by real-time PCR as a minimal residual disease marker after transplant.

19 te that microvascular reactivity is an early disease marker and advocate establishing therapies that

20 ion with prostate carcinogenesis can provide disease markers and clues relevant to disease etiology.

21 e be used for screening single molecules for disease markers and for monitoring individual molecular

22 s a platform for the identification of early disease markers and for the efficient testing of novel t

23 y, we correlated each PTP locus with genetic disease markers and identified 4 PTPs that map to known

24 lymphoblastic leukaemia are well established disease markers and indicators of outcomes.

25 tionary tool for ultrasensitive detection of disease markers and infectious agents.

26 airment on treatment, whereas cardiovascular disease markers and inflammatory markers are.

27 lls is inversely associated with HIV-related disease markers and linked with delayed disease progress

28 way for considering CRMPs as potential early disease markers and modulation of their activity as ther

29 itative microRNA detection, the discovery of disease markers and non-invasive early diagnosis of canc

30 f the Bcr-Abl fusion kinase highlights novel disease markers and potential drug-responsive biomarkers

31 from population genomics are identifying new disease markers and potential novel drug targets to bett

32 We also consider the use of matrikines as disease markers and potential therapeutic targets in lun

33 fferentiation; they could be investigated as disease markers and potential therapeutic targets.

34 splice variants of these genes might provide disease markers and targets for novel therapeutics.

35 ther study of this network could lead to new disease markers and therapeutic targets for patients wit

36 itis B is usually a sustained improvement in disease markers and, when cirrhosis is considered, patie

37 e independently related to other Alzheimer's disease markers, and to examine individuals who are disc

38 erous studies, and several other Alzheimer's disease markers are emerging in the literature.

39 ations are replicating a previously reported disease-marker association but with the risk allele reve

40 We model disease-marker association in a candidate region via a h

41 fine map genes, investigators often test for disease-marker association in chromosomal regions with e

42 Case-control disease-marker association studies are often used in the

43 n important issue in case-control studies of disease-marker association, even within populations cons

44 linkage in the marker region, even given no disease-marker association.

45 n presumed to cause many of the unreplicated disease-marker associations reported in the literature,

46 ) has enabled the detection of pathogens and disease markers at extremely low levels.

47 The ability to detect disease markers at the single molecule level promises th

48 MicroRNAs show promise as disease markers because of their cell type-specific expr

49 This technology is also used to detect disease markers beyond acylcarnitines and amino acids, a

50 3-nitrotyrosine formation may not only be a disease marker but may also be involved in the pathogene

51 ication algorithm to identify discriminative disease markers by learning on bipartite graphs.

52 Early detection of disease markers can provide higher diagnostic power and

53 t in the cytoplasmic domain of the Hodgkin's disease marker, CD30, and binds TRAF3 in vitro.

54 anies to provide information on exposure and disease markers, clinical trial design for safety and ef

55 each individual based on patient preference, disease markers, consequences of relapse, safety, and co

56 ltrasensitive in vivo multiplexed tumour and disease marker detection.

57 can be constructed using any genotype-based disease-marker disequilibrium measure and is asymptotica

58 fibrosis, reduced gene expression of several disease markers for hypertrophy and extracellular matrix

59 using a low-density microarray containing 80 disease marker genes.

60 at followed, other cytogenetic and molecular disease markers have been described and effectively inco

61 We examined two proteins used as disease markers, human C-reactive protein (CRP) and huma

62 significantly improved in two patients, and disease markers improved or stabilized in three patients

63 be considered when using the neoepitope as a disease marker in arthritis.

64 We obtained disease markers in 62 patients with VCI that included ne

65 er than whole bile, for developing miR-based disease markers in bile.

66 ications including the analysis of candidate disease markers in complex mixtures such as serum.

67 lammatory receptor expression or function as disease markers in patients with heart failure.

68 in suppressing viral activity and improving disease markers in short-term studies.

69 relationship between GBV-C infection and HIV disease markers in the context of highly active antiretr

70 will enable real-time optical assessment of disease markers in the living body.

71 of HML-2 expression was not related to HIV-1 disease markers in this patient cohort.

72 ependent Galectin-1 binding induced a set of disease markers, including matrix metalloproteinases and

73 (adenosine, 18 microM detection limit), to a disease marker (interferon-gamma of tuberculosis, 2.6 nM

74 Chronic abdominal pain without a biological disease marker is similar to irritable bowel syndrome, i

75 The lack of a recognizable disease marker makes this condition difficult to identif

76 and perhaps even the gut, may correlate with disease markers of atherosclerosis.

77 ctures towards ultrasensitive biosensing for disease markers or pathogens is of high importance.

78 ciations between heavy marijuana use and HIV disease markers or white blood cell (WBC) count were exa

79 No significant change in plasma metabolic disease markers over the study period was observed, but

80 and therefore amenable to the development of disease marker panels.

81 we demonstrate the quantitative analysis of disease-marker proteins by continuously separating the a

82 binding sites in LMP1 and the CD30 Hodgkin's disease marker provides further evidence that a TRAF3-me

83 rovide a fast and systematic way to identify disease markers relevant to clinical care.

84 interval: BM disease resolved and all other disease markers significantly improved in two patients,

85 HIV disease markers, such as viral load and CD4 cell counts,

86 are dependent on the qualification of these disease markers that are intended to be substitutes for

87 e used as molecular imaging probes to target disease markers, thereby extending applications of MRI.

88 uture prospects, ranging from the search for disease markers to challenging developments such as stem

89 ys to produce new behaviors, thereby linking disease markers to noninvasive sensing and reprogrammed

90 Label-free nanosensors can detect disease markers to provide point-of-care diagnosis that

91 fications, additional testing for infectious disease markers, viral inactivation processes, and refin

92 high potential of FERS for the detection of disease markers was demonstrated with the analysis of 27

93 al agents, possible contributing factors, or disease markers-well demonstrated in animal models-remai

94 Disease markers were detected using nanoparticles to pro

95 stically significant associations with these disease markers were found for the CBD cases with the DD

96 nostic algorithms that incorporate molecular disease markers, which complement histological impressio

97 s providing molecular contrast of endogenous disease markers with subcellular spatial resolution have

98 may lead to greater insights on subclinical disease markers without apriori assumptions of causality

99 proteins within single biological cells for disease markers without performing polymerase chain reac

100 treatments have appeared promising based on disease markers, yet caused harm when tested in studies